I truly think so. The real hurdle is to get into a collaboration with a reasonably organized healthcare provider that lets you access a sufficiently large pool of donors, with electronic health records and the capability to follow them up.
Bonus points if you can genotype them, i.e. measure common genetic variants using a chip similar to e.g. the one used by 23andme. Most tumors have an association with variants in the HLA region, and pre-screening susceptible individuals will reduce sample sizes and therefore initial costs to bootstrap.
The same applies to TCR-seq and other biomarkers which are incredibly useful to detect autoimmune disorders really early in the process.
In case you are interested in discussing this further, just get in touch via email (on my profile).
Bonus points if you can genotype them, i.e. measure common genetic variants using a chip similar to e.g. the one used by 23andme. Most tumors have an association with variants in the HLA region, and pre-screening susceptible individuals will reduce sample sizes and therefore initial costs to bootstrap.
The same applies to TCR-seq and other biomarkers which are incredibly useful to detect autoimmune disorders really early in the process.
In case you are interested in discussing this further, just get in touch via email (on my profile).